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Abstract
Background: The aim of this study was to assess the effect of trans-tricuspid placement 
of permanent pacemaker (PPM), implantable cardioverter defibrillator (ICD) and cardiac 
resynchronization therapy (CRT) leads prospectively on tricuspid valve and right-sided heart 
functions using two-dimensional echocardiography.
Methods: A total of 41 patients (31 male, mean age: 63.6 ± 12.2 years) were included in this 
prospective study. Initial echocardiographic evaluation was performed before cardiac device 
implantation and re-evaluation by echocardiography was performed immediately after the pro-
cedure and at 1st, 6th and 12th months. In addition to standard echocardiographic examinations, 
vena contracta (VC), proximal isovelocity surface area (PISA), and tissue Doppler evaluations 
were also performed in the study population.
Results: Tricuspid regurgitation (TR) is worsened by 1 grade in 70.8% of the patients and  
2 grades in 17.1% of the patients in the follow-up. Eight patients without baseline TR developed 
new-onset TR (9.8% mild, 9.8% moderate) after lead implantation. In the follow-up period, 
41.5% of the patients who had mild TR before lead implantation developed moderate TR and 
7.3% developed severe TR, whereas 19.5% of the patients with moderate TR developed severe 
TR during the follow-up. In the follow-up period, VC of TR was increased [median: 0.32 
(0.16–0.60) cm in pre-implantation period, and 0.41 (0.18–0.80) cm at 12th month, p = 0.001].  
Similarly PISA value of TR was also increased [median: 0.46 (0.15–1.10) cm in pre-implanta-
tion period and 0.52 (0.28–1.20) cm at 12th month, p = 0.001]. However, there is not a significant 
difference between PPMs/ICDs and CRTs regarding the effects on TR (p < 0.05). In addition, 
right ventricular dimensions and right atrial volumes were increased during the follow-up.
Conclusions: Implantation of permanent transvenous right ventricular electrode is associa-
ted with worsening of TR, right atrial and right ventricular dimensions. Further studies are 
needed in order to both outline the effect of those findings on outcomes and clarify the time 
dependent changes in those functions. (Cardiol J 2015; 22, 6: 637–644)
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functions, permanent pacemaker, implantable cardioverter defibrillator
637www.cardiologyjournal.org
ORIGINAL ARTICLE
Cardiology Journal 
2015, Vol. 22, No. 6, 637–644
DOI: 10.5603/CJ.a2015.0060
Copyright © 2015 Via Medica
ISSN 1897–5593
Introduction
Implantable cardioverter defibrillators (ICDs) 
and permanent pacemakers (PPMs) are commonly 
used devices for the treatment of cardiac conduc-
tion disorders and life threatening arrhythmias in 
the current practice. With the advent of newer 
technologies and implantation techniques, the 
number of implanted devices has been increased 
all over the world [1]. Nevertheless, implantation 
of these devices is an invasive procedure and which 
is associated with several early and late complica-
tions. Despite the most stressed periprocedural 
complications relevant mainly to cardiac device, 
tricuspid regurgitation (TR) due to right ventricle 
(RV) endocardial lead implantation is a commonly 
observed but mostly an overlooked condition.
Tricuspid regurgitation is a frequently ob-
served valvular disease and the mechanism of TR 
is mostly due to the secondary causes resulting in 
RV and tricuspid annular dilatation [2]. However, 
there are several proposed mechanisms causing TR 
and RV dysfunction after lead implantation. Endo-
cardial lead implantation can cause structural TR 
due to deformity of valve including adherence and 
impingement of electrodes to valvular structures 
or perforation of valve and its components [3, 4]. 
In addition, high percentage of RV pacing might 
cause TR due to atrioventricular discordance with 
unicameral ventricular pacing mode. Moreover, re-
current thrombus embolization from cardiac leads 
might also cause pulmonary hypertension and TR 
due to RV dilatation [5].
Current knowledge regarding the effects of 
cardiac leads on tricuspid valve functions largely 
based on retrospective or observational studies. 
Moreover, there is paucity of data about the effects 
of lead implantation on right-sided heart functions 
especially evaluated by more quantitative methods. 
In the light of those data, in this prospective study, 
we aimed to evaluate the prevalence and severity 
of TR and effect of trans-tricuspid lead implantation 
on both tricuspid valve and right sided heart cham-
bers’ functions, using 2-dimensional and Doppler 
echocardiography in a group of patients referred 
for PPM, ICD or cardiac resynchronization therapy 
(CRT) implantation.
Methods
Study population
In this prospective study, we enrolled a con-
secutive of subset patients who had transtricuspid 
implanted PPM/ICD or CRT leads according to the 
indications as assessed by guidelines [6]. Patients 
with severe stenosis or regurgitation in atrio-
ventricular or semilunar valves and a history of 
previous tricuspid valve repair were excluded from 
the analysis. All of the patients were evaluated 
with 2 dimensional (2D)-echocardiography before 
and 3 times after the cardiac device implantation 
(1st, 6th  and 12th months after the procedure).
Medical history of hypertension, hypercholes-
terolemia, coronary artery disease (CAD), diabetes 
mellitus (DM), chronic obstructive pulmonary 
disease (COPD), family history of CAD and cur-
rent medications were systematically evaluated. 
Pre- and post-implantation data of the leads were 
all collected from the study population. All RV 
leads of PM and ICD’s were implanted in the RV 
apex and left ventricular (LV) electrodes of CRT 
in the posterolateral branch of coronary sinus. In 
our study group, we used pacemaker, ICD and CRT 
of St. Jude family; DDD Zephyr (St. Jude Medical, 
MN, USA) for pacemaker, Fortify Assura ICD (St. 
Jude Medical, USA) for DDD-ICD and Unify Quadra 
or Quadra Assura models (St. Jude Medical, USA) 
for CRT-D. The PM/ICD settings were individually 
programmed based on the indication for cardiac 
devices. In order to decrease the detrimental ef-
fects of RV pacing, atrioventricular interval was 
lengthened in appropriate patients based on the 
indication of implantation. The target percent-
age of CRT stimulation was > 95% in the study 
population which was achieved in all patients. All 
devices were interrogated in our center at the time 
of routine control visits (1st, 6th and 12th months) 
after the procedure. Informed consent was obtained 
from each patient and this study was approved by 
the local Ethics Committee.
Echocardiographic evaluation
Standard echocardiographic imaging was per-
formed in the left lateral decubitus position in the 
parasternal and apical views. Two-dimensional, 
M-mode, pulsed and color flow Doppler echo-
cardiographic examinations of all subjects were 
performed by the same examiner with a commer-
cially available machine (Vingmed System Five GE 
ultrasound, Horten, Norway, 2.5–3.5 mHz phased 
array transducer) who was blinded to the clinical 
details of the subjects in the study group. Dur-
ing echocardiography, a 1-lead electrocardiogram 
was recorded continuously. Left ventricular end-
diastolic (LVEDD), left ventricular end-systolic 
(LVESD), RV size and right atrial (RA) major and 
minor dimensions were measured from parasternal 
long-axis views and apical views according to the 
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standards of the American Society of Echocardi-
ography [7]. The ejection fraction of RV and LV 
was measured according to the guidelines by using 
modified Simpson method [8]. Right atrial maxi-
mum and minimum diameters and three different 
RV size (RV1, on the level of tricuspid annulus; 
RV2, on level of mid-ventricular part and RV3, lon-
gitudinal dimension from apex to annulus) were 
also measured [8]. Morphological and functional 
features of aortic, mitral, tricuspid valve and pulmo-
nary valves were analyzed according to generally 
accepted guidelines and TR was graded as absent, 
trace, mild, moderate and severe based on the jet 
area by color Doppler.
Tricuspid inflow indices were obtained by 
pulsed-wave Doppler from the apical 4-chamber 
view to assess RV filling. The tricuspid annular 
plane systolic excursion (TAPSE) examination for 
RV function and vena contracta (VC) width, and 
proximal isovelocity surface area (PISA) measure-
ments for TR were performed in all participants 
according to the recommended guidelines [8]. The 
degree of TR was classified as mild, moderate and 
severe using VC width (VC < 0.3 cm for mild TR, 
VC 0.3–0.7 for moderate TR and VC > 0.7 for severe 
TR) and PISA (PISA < 0.5 cm for mild TR; PISA 
0.5–0.9 cm for moderate TR and PISA > 0.9 cm 
for severe TR) [9].
Tissue Doppler imaging echocardiography was 
performed by transducer frequencies of 3.5–4.0 MHz, 
adjusting the spectral pulsed Doppler signal filters 
until a Nyquist limit of 15–20 cm/s was reached 
and using the minimal optimal gain. The monitor 
sweep speed was set at 50–100 mm/s to optimize 
the spectral display of myocardial velocities. The 
pulsed-wave tissue Doppler imaging  was per-
formed in the apical views by placing a 3 mm 
sample volume at the level of left ventricular 
lateral mitral annulus, septal mitral annulus, and 
RV tricuspid annulus. The sampling window was 
positioned as parallel as possible with the myo-
cardial segment of interest to ensure the optimal 
angle of imaging. Peak systolic (S’), early (E’) 
and late diastolic myocardial velocities (A’) were 
recorded. Several cardiac cycles were evaluated 
and the best three consecutive ones were analyzed 
and averaged.
Follow-up
In the follow-up period, clinical assessment, 
cardiac device evaluation and echocardiographic 
examination were all performed. Echocardio-
graphic examination was repeated after 1st, 6th and 
12th months in the follow-up period. All of the 
patients included in the analysis completed the 
follow-up controls.
Statistical analysis
Statistical analyses were made using Statistical 
Package for Social Sciences (SPSS) (IBM SPSS Inc. 
Chicago, IL) and Medcalc 11.4.2. (Medcalc Soft-
ware, Mariakerke, Belgium). Normally distributed 
continuous parameters were presented as mean ± 
± standard deviation and skewed continuous param-
eters were expressed as median (interquartile range 
defined as Q1–Q3). Categorical data were presented 
as frequencies and percentages and were com-
pared using c2 test. Comparisons between baseline 
characteristics were performed with independent 
student’s t, Mann-Whitney rank-sum, Fisher exact 
or c2 tests where appropriate. The change in the 
follow-up period was evaluated by using ANOVA 
in normally distributed data and Friedman test in 
abnormally distributed data. A 2-tailed p < 0.05 was 
considered statistically significant.
Results
Basal clinical and echocardiographic  
characteristics
A total of 41 patients (31 male, 75%) with 
a mean age of 63.6 ± 12.2 years were enrolled in 
the analysis. Among the study population, 61% 
had hypertension, 36.6% had DM and 7.3% had 
COPD. A total of 41 cardiac devices were implanted 
and 25 (61%) were DDD ICD, 9 (22%) of them 
were CRT-D and 7 (17%) were DDD PM. Among 
those patients, 1 (2.5%) patient had aortic valve 
replacement (AVR), 1 (2.5%) patient had mitral 
valve replacement (MVR) and 1 (2.5%) patient had 
both AVR and MVR in the past medical history. 
The baseline characteristics of the patients are 
described in Table 1.
Before PM implantation all patients had com-
plete echocardiographic examinations including 
both LV and RV functions. The mean ejection 
fraction, LVEDD and LVESD of the study group 
were 34.2 ± 13.1%, 60.2 ± 9.6 mm and 47.8 ± 
± 11.2 mm, respectively. In the study group, 
trace-mild TR was found in 31 (75%) patients 
and moderate TR was found in only 10 (25%) 
patients. The baseline TAPSE value of the study 
group was 18.9 ± 3.4 mm and the mean pulmonary 
artery pressure (PAP) was 35.5 ± 3.7 mm Hg. 
The tissue Doppler parameters measured 
from tricuspid annulus were 7.5 ± 3.1 cm/s 
for E; 11.7 ± 4.1 cm/s for A and 9.5 ± 2.2 cm/s for 
S. During the follow-up period, statistically signifi-
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cant difference was not observed regarding TAPSE, 
PAP or tissue Doppler parameters (p > 0.05) 
(Table 2). Moreover, those parameters did not 
show statistical difference when the device type 
considered.
Effect of lead implantation on TR  
measured by color flow jet
During the 1-year follow-up, a statistically sig-
nificant increase in TR was observed in the study 
population which is independent from the lead type 
implanted (p = 0.001). Before device implantation 
8 (19.5%) patients were free of TR, 23 (56.1%) 
patients had trace-mild TR and 10 (24.4%) patients 
had moderate TR. After device implantation mild 
TR was developed in 4 (9.8%) patients and moderate 
TR was developed in 4 (9.8%) patients who did not 
have any TR before device implantation (p < 0.05). 
Among the 23 patients having trace-mild TR at 
the beginning of the study, 17 (41.5%) developed 
moderate TR and 3 (7.3%) patients developed 
severe TR (p < 0.05) during the follow-up period. 
Similarly, there was an increase in the grade of TR 
also among 10 patients having moderate TR before 
lead implantation. While 8 (19.5%) of those patients 
developed severe TR in the follow-up period, 
2 patients remained in the moderate TR grade after 
lead implantation during the follow-up (p < 0.05).
As a result, after lead implantation, compared 
to basal levels, TR was worsened by at least 1 grade 
in 70.8% of the study population and 2 grades in 
17.1% of the whole study population during the 
follow-up. The change in TR grade was observed 
at the 1st month of the follow-up when compared 
to preimplantation period (p = 0.001), however 
difference in TR grade was not significant between 
1st month and 6th–12th months values in all device 
types (Fig. 1).
Table 2. The change in the tissue Doppler parameters, tricuspid annular plane systolic excursion,  
pulmonary artery pressure, and inferior vena cava during the follow-up (p value indicating the  
significance within group).
Variable Post-implantation 1st month 6th month 12th month P
TAPSE (mm] 18.93 ± 3.43 18.88 ± 3.21 18.46 ± 3.45 18.34 ± 3.79 0.213 
E’ [cm/s] 7 (3–16) 8 (3–17) 8.1 (4–14) 7.7 (3–16) 0.353
A’ [cm/s] 11 (4.5–23) 12 (4–26) 10 (3–24) 12 (3–25) 0.270
S’ [cm/s] 9.9 (4.6–20) 10 (5.7–18) 9.7 86–17) 9.5 (4–19) 0.691
PAP [mm Hg] 35 (20–75) 35 (25–70) 35 (25–85) 35 (20–75) 0.420
IVC size [mm] 15.71 ± 2.94 16.17 ± 2.77 16.39 ± 2.91 16.61 ± 2.64 0.085
IVC — inferior vena cava; PAP — pulmonary artery pressure; TAPSE — tricuspid annular plane systolic excursion
Table 1. Baseline characteristics of the study 
population.
Variable Study population  
(n = 41)
Age [years] 63.6 ± 12.2
Male gender 31 (75.6%)
Body mass index [kg/m2] 28.5 ± 3.3
Hypertension 25 (61%)
Diabetes mellitus 15 (36.6%) 
COPD 3 (7.3%)
CAD 32 (78%)
Hyperlipidemia 34 (82.9%)
Medications
Beta-blockers 38 (92.7%)
ACE/ARB 31 (75.6%)
Diuretics 20 (48.8%)
Acetylsalycyclic acid 31 (75.6%)
Statin 26 (63.4%)
Previous cardiac operation
AVR 1 (2.4%)
AVR + MVR 1 (2.4%)
MVR 1 (2.4%)
Cardiac device types
CRT-D 9 (21.9%)
DDD 7 (17%)
DDD-ICD 25 (61%)
Tricuspid regurgitation severity
Absent–minimal 8 (19.5%)
Mild 23 (56.1%)
Moderate 10 (24.4%)
Severe –
PAP [mm Hg] 35.5 ± 3.7
ACE — angiotensin converting enzyme; ARB — angiotensin recep-
tor blocker; AVR — aortic valve replacement; CAD — coronary 
artery disease; COPD — chronic obstructive pulmonary disease; 
CRTD — cardiac resynchronization therapy with defibrillator;  
ICD — implantable cardioverter defibrillator; MVR — mitral valve 
replacement; PAP — pulmonary artery pressure
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Effect of lead implantation on TR  
measured by semiquantitative and  
quantitative methods
In the follow-up period, VC of TR was in-
creased significantly and progressively in every 
follow-up period (median: 0.32 [0.16–0.60] cm in 
pre-implantation period, and 0.41 [0.18–0.80] cm at 
12th month, p = 0.001). Similarly, PISA value was 
also increased in the follow-up period for TR (me-
dian: 0.46 [0.15–1.10] cm in pre-implantation period 
and 0.52 [0.28–1.20] cm at 12th month, p = 0.001) 
as shown in Table 3. However, there was no statisti-
cally significant difference between implanted lead 
types and VC and PISA values of the TR between 
during the follow-up period (p = 0.074 and p = 
= 0.192, respectively). The trend of change in PISA 
and VC values were shown in Figure 2.
Effect of lead implantation on RA and RV 
dimensions and functions
When compared to basal values, RV diameters 
showed progressive increase after cardiac device 
implantation at the 12th month. In the study group, 
RV1, RV2 and RV3 dimensions were as follows: 
3.5 ± 0.3 cm vs. 3.7 ± 0.3 cm; 2.9 ± 0.3 cm vs. 
3.0 ± 0.3 cm; 7.5 ± 0.7 vs. 7.7 ± 0.7 cm, respec-
tively (p < 0.001). Similar to the TR, the change 
in RV diameters did not differ between cardiac 
device types. Among RA maximum and minimum 
diameters, RA maximum diameter did not change 
at 12th month significantly when compared to basal 
value (51.4 ± 8.5 cm vs. 51.9 ± 9.4 cm, p = 0.486) 
Figure 1. Change in tricuspid regurgitation (TR) between 
cardiac device types assessed by color flow jet.
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tors were more familiar compared to right side. 
The RV has a complex anatomy and a nonplanar 
annulus. The 2D echocardiography necessitates 
multiple views to assess the tricuspid valve and 
its functions. However, the exact mechanism 
of TR due to electrode damage was diagnosed 
with transesophageal echocardiography (TEE) in 
only 12% of patients in 1 study [10]. In another 
retrospective study, TR due to lead injury was 
detected in only 22% of patients with transtho-
racic echocardiography (TTE) and 45% with TEE 
[10]. Therefore, despite the common knowledge 
on the possible mechanisms of TR after cardiac 
device implantation, the clear evidence to explain 
the whole spectrum of TR could not be obtained 
using 2D TTE or TEE. However, with the more 
common usage of 3D echocardiography, insights to 
the definitive mechanisms of TR and relationship 
between TR and implanted leads can be defined 
more precisely [11].
The data regarding the prevalence of TR devel-
opment after endocardial lead insertion is diverse 
[12–15]. Most of the studies were in retrospective 
nature and included small number of patients. 
Increased severity of TR has been reported to be 
associated with increased mortality and decreased 
life quality regardless of LV ejection fraction or PAP 
[13]. In a previous study, Nath et al. [16] and Höke 
et al. [17] reported reduced survival after PPM/ICD 
Figure 2. Change in vena contracta (VC) (A) and proximal isovelocity surface area (PISA) (B) during the follow-up compared 
to basal levels for all cardiac device types (p < 0.005 between preimplantation and 12th month for both VC and PISA).
however RA minimum diameter showed significant 
increase compared to baseline value (40.4 ± 8.7 cm 
vs. 43.1 ± 7.6 cm, p < 0.05).
In addition to the changes in RV dimensions, 
ICD/PPM implantation was also associated with 
worsening in RV ejection fraction. Compared 
to preimplantation values, RV ejection fraction 
decreased significantly throughout the follow-up 
period irrespective of the device type implanted 
(39.9 ± 10.1% at pre-implantation period, 36.4 ± 
± 9.6% at 1st month, 32.7 ± 9.5% at 6th month and 
29.7 ± 9.9% at the 12th month, p < 0.001).
Discussion
With the advent of cardiac device implantation 
via endocardial route, many researchers proposed 
that PM/ICD electrodes worsen tricuspid insuf-
ficiency as they pass through the tricuspid orifice 
[3, 10]. However, to the best of our knowledge, there 
is not any prospective study in the literature which 
evaluated the effects of PM/ICD lead implantation 
via endocardial route on both tricuspid valve and 
right chamber functions. In this study, our findings 
indicated that PM/ICD/CRT-D implantation causes an 
increase in tricuspid insufficiency and deterioration in 
RA and RV dimensions and decrease in RV functions.
Evaluation of right heart chambers is different 
from the left side where most of the investiga-
642 www.cardiologyjournal.org
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implantation in patients who had moderate or 
severe TR when compared to patients with no or 
minimal TR. Similarly, a recent retrospective study 
by Al-Bawardy et al. [18] reported that in addition 
to the trend with worsening TR, TR after cardiac 
device implantation was also associated with de-
creased survival. Our findings were also in line with 
the aforementioned data which clearly outline the 
detrimental effects of cardiac device implantation 
on tricuspid valve functions.
An important aspect of the change in TR and 
RV functions is the assumption of differential ef-
fects of various cardiac device types regarding to 
the inherent properties of those devices like thick-
ness of coils, flexibility and number of electrodes 
passing through the tricuspid valve. In a previous 
study, involving 248 patients with ICD or PPM, 
Kim et al. [12] reported that ICDs cause more TR 
than normal PPM (32.4% vs. 20.7%, p < 0.05) and 
attributed this difference to less flexible and thicker 
nature of ICD electrodes and shocking coil causing 
more fibrosis at the neighboring areas of tricuspid 
valve. However, an important finding in our study 
which should be stressed is the lack of association 
between cardiac device types and TR and changes 
in RV functions, despite a statistically significant 
TR increase after PPM/CRT or ICD implantation. 
Our findings are also in line with a large scale 
retrospective analysis which reported a similar 
increase in TR with both ICD and PPM placement 
irrespective of the number of leads implanted or 
the device type used [18]. However, implantation 
technique, as well as the type of ICD lead might 
have a potential to affect those outcomes which 
deserves to be investigated in prospective studies 
with a higher number of patients included.
After PM/ICD lead implantation, tricuspid 
insufficiency might develop or worsen due to 
several proposed mechanisms including physical 
impingement of lead on the valve, fibrous tissue 
formation causing adherence and rarely perforation 
and entrapment of lead with valvular apparatus 
[19–22]. In addition, the clinical presentation of 
acute insult to the integrity of valvular or subval-
vular apparatus might cause clinical findings in 
a more chronic nature depending on both baseline 
ventricular functions and pulmonary hypertension. 
An interesting finding in our study is the differen-
tial pattern of worsening in TR evaluated by color 
jet method or more quantitative methods like VC or 
PISA measurements. While color jet method indi-
cated deterioration in TR in an acute pattern within 
the 1st month after lead implantation, VC and PISA 
of the patients increased gradually throughout the 
follow-up period. However, the clinical significance 
and prognostic value of such pattern is not known.
The evaluation of the mechanisms after cardiac 
device implantation revealed that lead impingement, 
adherence, perforation and entanglement plays an 
important role in the formation of TR [10, 13]. In ad-
dition to those mechanisms, asynchrony due a high 
ratio of RV pacing causing deterioration in both right 
and right ventricular functions and tricuspid annular 
dilatation should not be overlooked [23]. Although 
some studies demonstrated beneficial effect of CRT 
pacing for RV functions, the number of patients with 
CRT is small in our study population preventing to 
make certain and definitive conclusions about the 
RV functions in those patients [24]. Despite the 
high pacing ratio in CRT patients, the ventricular 
pacing ratio is not > 10% with PPM/ICD’s in our 
study population that might cause a bias effect in 
TR grade. Moreover, an increase in PAP can also 
cause TR. As demonstrated in previous studies, the 
increase in TR was not associated with an increase 
in PAP values [12, 18].
An important issue regarding the evaluation 
of TR is the quantitativity of the method we se-
lected. Due to the retrospective nature of most 
of the studies evaluating this issue previously, 
TR jet area or ratio of regurgitation jet area to 
RA area based measurements were frequently 
used to determine the degree of TR. However, 
this method has the potential to underestimate 
TR severity especially when the RA is dilated. 
Moreover, in case of small difference in the sys-
tolic pressure between RA and RV, TR could be 
underestimated when TR jet area used. Because 
of those pitfalls, VC gained an interest in order to 
evaluate the severity of TR more quantitatively 
[23]. Therefore, different from previous studies, 
more quantitative methods of VC and PISA for TR 
was used in our study in additional to conventional 
TR color jet based grading which revealed an in-
crease in PISA and VC values progressively and 
significantly in the follow-up period, as well as RA 
volumes and RV diameters. Although none of the 
patients in our study group additional worsening 
in symptomatic status or clinical right heart failure 
symptoms after cardiac device implantation, the 
follow-up period is not enough to exactly assess 
the change in those novel parameters for TR 
grading and clinical outcomes. Therefore, the as-
sociation of those novel TR grading parameters 
should be evaluated in large scale studies which 
might also aid to determine the patient subgroups 
before clinically evident deterioration in sympto-
matic status.
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Limitations of the study
Our study has some limitations. First, we 
used 2D echocardiography for the evaluation of TR 
and RV functions. However, 3D echocardiography 
might give important clues especially regarding the 
exact mechanism of TR in this study population. 
Nevertheless, we used more quantitative param-
eters determined by the guidelines to evaluate TR 
and right heart functions optimally. Second, despite 
the prospective nature of our study, our study popu-
lation is not large enough to determine effect of TR 
worsening on cardiovascular survival. Therefore, 
large scale prospective studies are needed in order 
to evaluate the clinical significance of those novel 
parameters on clinical outcomes. Also, our study is 
a single center study involving mostly the patients 
with decreased LV functions which is an important 
limitation to extrapolate those findings in a more 
general group of patient population.
Conclusions
In conclusion, the implantation of electrodes 
for PPM/CRT or ICD might cause worsening of 
TR and RV functions. However this effect is in-
dependent of the device implanted in our study 
population. Further studies are needed especially 
with novel imaging modalities in order to clarify 
the exact mechanisms of TR and RV dysfunction 
as well as optimal management of worsening TR 
after cardiac device implantation.
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